Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report
(Date of
earliest event reported):
March 2,
2009
Enzo
Biochem, Inc.
|
(Exact
Name of Registrant as Specified in Its
Charter)
|
New
York
|
(State
or Other Jurisdiction of
Incorporation)
|
001-09974
|
13-2866202
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
527
Madison Avenue
|
|
New
York, New York
|
10022
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(212)
583-0100
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02. Departures of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(b) and
(c) Effective March 2, 2009, Kevin Krenitsky
MD has replaced Shahram K. Rabbani as President of Enzo Clinical Labs, Inc.
(“Enzo Labs”), a wholly-owned subsidiary of Enzo Biochem, Inc. (the
"Company"). Prior to joining the Enzo Labs, Dr. Krenitsky served as
the Chief Executive Officer (CEO) of BioServe, a Maryland based genomics
services company that provides genetic analysis to pharmaceutical and research
organizations. In this capacity, Dr. Krenitsky led a team of highly
competent executives in a global expansion of the company, by extending
institutional equities and executing strategic acquisitions. From
2006 to 2007, Dr. Krenitsky served as the CEO of Parkway Clinical Labs
(“Parkway”), which is a regional full service and esoteric reference laboratory
in Pennsylvania. From 2005 to 2006, Dr. Krenitsky served as Parkway’s Senior
Vice President and Division Head, and from 2004 to 2005 he served as
Parkway’s Senior Vice President of Business Development. The Company
believes that Dr. Krenitsky’s experience and talent will be a key component to
achieving our business goals.
There are
no family relationships between Dr. Krenitsky and any of the executive officers
or directors of the Company or any of its affiliates.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ENZO
BIOCHEM, INC.
|
|
|
|
|
|
Date: March
5, 2009
|
By:
|
/s/
Barry Weiner |
|
|
|
Barry
Weiner |
|
|
|
President,
Chief Financial Officer and Director
|
|
|
|
|
|